Kevin Hanaway, APRN
Primary Care · Fort Lauderdale, FLNPI 1447666086
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,915 of the $11,619 with a category attached, or 68.1%. GSK accounts for 79.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2021 at $5,333 and has fallen 81.5% since, to $989 in 2025. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $76.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- AstraZeneca$443
- Boehringer Ingelheim$401
- Actelion Pharmaceuticals US, Inc.$235
- Mylan Specialty L.p.$161
- Sanofi$145
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$7,91568%
- Food & beverage$3,59931%
- Education$1051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 41 | $9,193 |
| AstraZeneca | 19 | $443 |
| Boehringer Ingelheim | 26 | $401 |
| Actelion Pharmaceuticals US, Inc. | 6 | $235 |
| Mylan Specialty L.p. | 7 | $161 |
| Sanofi | 5 | $145 |
| Insmed, Inc. | 7 | $132 |
| Regeneron Healthcare Solutions, Inc. | 7 | $129 |
| United Therapeutics Corporation | 4 | $105 |
| Verona Pharma, Inc. | 4 | $92 |
| Novartis | 3 | $88 |
| Viatris Specialty LLC | 3 | $87 |
| Baxter Healthcare | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Merck | 3 | $57 |
| Grifols USA, LLC | 2 | $50 |
| Amgen | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Inogen, Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Electromed, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Mckesson Medical-surgical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$7,121
- NUCALA$103
- TEZSPIRE$102
How this compares
$11,619 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 188 | $179,044 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $30,090 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $20,181 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $18,787 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $16,816 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 46 | $8,388 |
| XareltoRivaroxaban | 12 | $6,629 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,082 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,058 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,552 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 119 | $3,149 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 21 | $1,487 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,192 |
| Prednisone | 155 | $913 |
| Montelukast Sodium | 58 | $796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $9,193 | $222,563272 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $443 | $41,23169 claims |
| Boehringer IngelheimStiolto Respimat | $401 | $16,81613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Fort Lauderdale
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
- Robert PerriPalm Coast$10K
- Jenna MinniJupiter$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.